Longfellow,
I believe it's very possible that the bottom 100 did no better than the SOC, the next 100 may have done little to no better, and that may very well have been the reason the trial design moved to survival. I don't know this, going by what I've heard from others, but the key is, what happens to roughly the top third of those in the trial, many of them are still alive, the least of which would be alive roughly 4.5 years, but the longest may be over a decade, we really don't know, and we won't until after the trial unblinds.
What I do believe we know is that people outside this trial have spoken out at times, and they've done very well. Some of them may have been in Phase 1, others received the drug under compassionate use, some may have been for cancers other than GBM, the point is, some people have some terrific long term benefits, peoples who's lives were thought to be in months to very few years. Are they cured, some may be thought to be, but with cancer you never can be totally certain.
Gary